Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Oleclumab in Resectable PDAC
NCT06060405Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Nov 2023
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and oleclumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Health Network. Primary endpoint: Percent change in CD8+ cell infiltration at 35 days. Started Nov 2023; status: recruiting.
02
Drugs
durvalumaboleclumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06060405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060405.